We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kitov

News List

Kitov's combo gets FDA approval in osteoarthritis and hypertension pharmafile
June 07, 2018
Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, after the FDA authorised the drug for the treatment of osteo
Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda americanpharmaceuticalreview
July 20, 2017
Kitov Pharmaceuticals announced results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo, in combination with Keytruda...
FDA grants Kitov waiver for new drug application filing fee europeanpharmaceuticalreview
April 07, 2017
The US Food and Drug Administration (FDA) has granted Kitov Pharmaceuticals a waiver related to the $2,038,100 new drug application filing fee for KIT-302.
FDA Grants Kitov a Waiver for New Drug Application Filing Fee americanpharmaceuticalreview
April 06, 2017
Kitov Pharmaceuticals Holdings Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application (NDA 210045) filing fee for...